Explore the iconic BioMarin logo – its design, history, and visual identity.
Key information about BioMarin: origin, designer, industry, and logo introduction year.
| Website | biomarin.com |
| Country | United States |
| Industry | Technology |
Explore the BioMarin brand, discover BioMarin colors, and download the BioMarin vector logo in SVG or PNG formats. Browse related logos and logos with similar colors.
BioMarin’s logo features a vibrant gradient wordmark spanning blue to magenta to red, representing the San Rafael, California biotechnology company pioneering enzyme replacement therapies for rare genetic diseases.
BioMarin Pharmaceutical Inc. was founded in 1997 in Novato, California before relocating to nearby San Rafael. The company focused on enzyme replacement therapies for rare genetic diseases, a market segment often neglected by major pharmaceutical companies due to small patient populations. BioMarin’s breakthrough came with laronidase (Aldurazyme), approved in 2003 as the first treatment for mucopolysaccharidosis type I (MPS I), a devastating lysosomal storage disorder affecting approximately 1 in 100,000 births.
The company expanded its rare disease portfolio through both internal development and acquisitions. BioMarin became the first company to provide therapeutics for phenylketonuria (PKU) with Kuvan, approved in 2007. Other products include Naglazyme for MPS VI, Firdapse for Lambert-Eaton myasthenic syndrome, and Vimizim for MPS IVA. The company achieved profitability in 2016, unusual for a biotechnology firm, demonstrating the viability of the rare disease model where high prices for small patient populations can sustain development costs.
However, BioMarin has faced criticism for aggressive pricing strategies. The company’s decision to price Brineura at $702,000 annually and other treatments at similar levels sparked debates about pharmaceutical pricing and patient access. BioMarin has also faced scrutiny for denying continued access to experimental drugs for some clinical trial participants after trials concluded, raising ethical questions about obligations to patients who helped develop therapies. Despite controversies, BioMarin employs over 2,800 people globally and had revenue exceeding $2 billion in 2022, establishing itself as a leader in rare disease therapeutics.
The BioMarin wordmark employs a gradient that flows from cool blue through vibrant magenta to warm red, creating a visually striking mark in the biotechnology sector where many competitors use conservative blue or green palettes. The gradient suggests the transformative nature of therapies that fundamentally alter patient outcomes. The deep navy (#062849) provides a scientific foundation, while the progression through purples (#263d96, #3a3899, #aa118e) and magentas (#ec047c) to reds (#ed192e, #f15029) creates energy and optimism. The text-only approach ensures legibility across scientific publications, medical conference materials, and patient education where the BioMarin name carries authority. The modern color treatment differentiates the company from traditional pharmaceutical firms while signaling innovation and scientific advancement that gives hope to rare disease communities.
Who designed the BioMarin logo? The BioMarin gradient wordmark was developed as part of the company’s corporate identity, though specific designer credits have not been publicly disclosed.
When was the BioMarin logo last updated? The gradient wordmark has represented BioMarin through its evolution from startup to profitable rare disease leader, with refinements to ensure consistency across global markets and digital platforms.
What do the colors in the BioMarin logo represent? The blue-to-magenta-to-red gradient represents the scientific foundation, innovative transformation, and life-saving impact of enzyme replacement therapies that address rare genetic diseases previously considered untreatable, creating hope for affected patients and families.
The BioMarin logo represents a technology brand from United States. Learn more on the official BioMarin website.
